{"nctId":"NCT02635386","briefTitle":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","startDateStruct":{"date":"2016-03-22","type":"ACTUAL"},"conditions":["Polycystic Ovary Syndrome","Obesity"],"count":119,"armGroups":[{"label":"Exenatide once weekly (EQW )","type":"EXPERIMENTAL","interventionNames":["Drug: Exenatide once weekly (EQW )"]},{"label":"Dapagliflozin (DAPA)","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin (DAPA)"]},{"label":"EQW plus DAPA","type":"EXPERIMENTAL","interventionNames":["Drug: EQW plus DAPA"]},{"label":"Dapagliflozin plus Glucophage (MET ER)","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin plus Glucophage (MET ER)"]},{"label":"Phentermine /Topiramate (PHEN/ TPM) ER","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Phentermine /Topiramate (PHEN/ TPM) ER"]}],"interventions":[{"name":"Exenatide once weekly (EQW )","otherNames":["• Bydureon","• Long acting glucagon like peptide 1 (GLP1) agonist"]},{"name":"Dapagliflozin (DAPA)","otherNames":["• Farxiga","• SGLT2 inhibitor"]},{"name":"EQW plus DAPA","otherNames":["Bydureon plus Farxiga","Long acting GLP1 agonist plus SGLT2 inhibitor"]},{"name":"Dapagliflozin plus Glucophage (MET ER)","otherNames":["Xigduo","•Combination SGLT2 inhibitor and metformin ER"]},{"name":"Phentermine /Topiramate (PHEN/ TPM) ER","otherNames":["Qsymia"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Non-diabetic women (18-45 years)\n2. PCOS- NIH criteria hyperandrogenism and irregular menses\n3. Obese class I, II, and III (BMI \\>30\\<45)\n4. Willing to use effective contraception consistently during therapy which is defined as:\n\n   1. an intrauterine device, tubal sterilization, or male partner vasectomy, or\n   2. combination of two barrier methods with one being male condom.\n5. Written consent for participation in the study\n\nExclusion Criteria:\n\n1. Presence of significant systemic disease, heart problems including congestive heart failure, unstable angina or acute myocardial infarction, current infectious liver disease, acute stroke or transient ischemic attacks, history of pancreatitis, or diabetes mellitus (Type 1 or 2)\n2. Any hepatic diseases in the past (infectious liver disease, viral hepatitis, toxic hepatic damage, jaundice of unknown etiology) or severe hepatic insufficiency and/or significant abnormal liver function tests defined as aspartate aminotransferase (AST) \\>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \\>3x ULN\n3. Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or estimated glomerular filtration rate (eGFR) \\<60 mL/min/1.73 m2) or history of unstable or rapidly progressing renal disease or end stage renal disease. Patients with a history of nephrolithiasis are also excluded due to increased association with kidney stone formation.\n4. Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital adrenal hyperplasia or hyperprolactinemia\n5. Significantly elevated triglyceride levels (fasting triglyceride \\> 400 mg/dL)\n6. Untreated or poorly controlled hypertension (sitting blood pressure \\> 160/95 mm Hg)\n7. Use of hormonal medications, lipid-lowering (statins, etc.), anti-obesity drugs or weight loss medications (prescription or OTC) and medications known to exacerbate glucose tolerance (such as isotretinoin, hormonal contraceptives, gonadotropin-releasing hormone agonists, glucocorticoids, anabolic steroids, C-19 progestins) stopped for at least 8 weeks. Use of anti-androgens that act peripherally to reduce hirsutism such as 5-alpha reductase inhibitors (finasteride, spironolactone, flutamide) stopped for at least 4 weeks\n8. Prior history of a malignant disease requiring chemotherapy\n9. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status\n10. History of unexplained microscopic or gross hematuria, or microscopic hematuria at visit 1, confirmed by a follow-up sample at next scheduled visit.\n11. Presence of hypersensitivity to dapagliflozin or other SGLT2 inhibitors (e.g. anaphylaxis, angioedema, exfoliative skin conditions\n12. Known hypersensitivity or contraindications to use GLP1 receptor agonists (exenatide, liraglutide)\n13. Use of metformin, thiazolidinediones, GLP-1 receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, SGLT2 inhibitors stopped for at least 4 weeks.\n14. Prior use of medication to treat diabetes except gestational diabetes\n15. Eating disorders (anorexia, bulimia) or gastrointestinal disorders\n16. Suspected pregnancy (documented negative serum pregnancy test), desiring pregnancy in next 6 months, breastfeeding, or known pregnancy in last 2 months\n17. Active or prior history of substance abuse (smoke or tobacco use within past 3 years) or significant intake of alcohol\n18. Having a history of bariatric surgery\n19. Patient not willing to use two barrier method contraception during study period (unless sterilized or have an IUD)\n20. Patients with glaucoma or history of increased intraocular pressure, or use of any medications to treat increased intraocular pressure\n21. Debilitating psychiatric disorder such as psychosis or neurological condition that might confound outcome variables. Patients with a history of bipolar disorder or psychosis, greater than one lifetime, episode of major depression, current depression of moderate or greater severity (PHQ-9score of 10 or more), presence or history of suicidal behavior or ideation with some intent to act on it, or antidepressant use that has not been stable for at least 3 months will also be excluded.\n22. Inability or refusal to comply with protocol\n23. Current participation or participation in an experimental drug study in previous three months\n\n    \\-","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Oral Disposition (Insulin Sensitivity-insulin Secretion) Index","description":"An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"471","spread":"83"},{"groupId":"OG001","value":"311","spread":"90"},{"groupId":"OG002","value":"503","spread":"80"},{"groupId":"OG003","value":"395","spread":"85"},{"groupId":"OG004","value":"545","spread":"93"}]}]}]},{"type":"SECONDARY","title":"Absolute Body Weight","description":"Treatment effect on body weight at 24 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.4","spread":"3.7"},{"groupId":"OG001","value":"102.6","spread":"4"},{"groupId":"OG002","value":"99","spread":"3.7"},{"groupId":"OG003","value":"101.2","spread":"3.8"},{"groupId":"OG004","value":"97","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Body Mass Index (BMI)","description":"Treatment efficacy in reducing body mass at 24 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":"1.1"},{"groupId":"OG001","value":"37.4","spread":"1.2"},{"groupId":"OG002","value":"36.7","spread":"1.1"},{"groupId":"OG003","value":"37","spread":"1.2"},{"groupId":"OG004","value":"35.3","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change in Percent Body Weight","description":"Treatment effect on change in percent body weight from baseline","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"0.8"},{"groupId":"OG001","value":"1.5","spread":"1.4"},{"groupId":"OG002","value":"6.9","spread":"0.9"},{"groupId":"OG003","value":"1.7","spread":"1.0"},{"groupId":"OG004","value":"8.1","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Central Adiposity (Waist Circumference)","description":"Treatment effect on loss of central adiposity after 24 weeks","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":"3"},{"groupId":"OG001","value":"101","spread":"3.2"},{"groupId":"OG002","value":"106","spread":"3"},{"groupId":"OG003","value":"101.3","spread":"3"},{"groupId":"OG004","value":"97","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Waist-to-Hip Ratio (WHR)","description":"Treatment impact on central adiposity after 24 weeks","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".83","spread":".016"},{"groupId":"OG001","value":".79","spread":".017"},{"groupId":"OG002","value":".86","spread":".016"},{"groupId":"OG003","value":".83","spread":".016"},{"groupId":"OG004","value":".81","spread":".018"}]}]}]},{"type":"SECONDARY","title":"Waist-to-Height Ratio (WHtR)","description":"Treatment impact on WHtR which is a measure of central adiposity","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".64","spread":".018"},{"groupId":"OG001","value":".61","spread":".02"},{"groupId":"OG002","value":".65","spread":".018"},{"groupId":"OG003","value":".61","spread":".019"},{"groupId":"OG004","value":".59","spread":".021"}]}]}]},{"type":"SECONDARY","title":"Total Fat Mass (kg) Evaluated by DEXA","description":"Treatment impact on total fat mass by DEXA","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":"2.4"},{"groupId":"OG001","value":"47.8","spread":"2.6"},{"groupId":"OG002","value":"45.9","spread":"2.4"},{"groupId":"OG003","value":"48","spread":"2.5"},{"groupId":"OG004","value":"44.5","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Total Body Fat (%) by DEXA","description":"Treatment impact on percent total body fat by DEXA","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":"1.1"},{"groupId":"OG001","value":"46.4","spread":"1.2"},{"groupId":"OG002","value":"45.8","spread":"1.1"},{"groupId":"OG003","value":"46.1","spread":"1.1"},{"groupId":"OG004","value":"45.2","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Android-Gynoid Ratio (AGR) as Determined by DEXA","description":"treatment impact on measure of central adiposity as determined by android/gynoid ratio","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":".024"},{"groupId":"OG001","value":"1.02","spread":".03"},{"groupId":"OG002","value":"1.04","spread":".02"},{"groupId":"OG003","value":"1.04","spread":".03"},{"groupId":"OG004","value":"1.03","spread":".03"}]}]}]},{"type":"SECONDARY","title":"Trunk/Leg Fat Ratio by DEXA","description":"Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":".045"},{"groupId":"OG001","value":".95","spread":".048"},{"groupId":"OG002","value":".93","spread":".045"},{"groupId":"OG003","value":".98","spread":".047"},{"groupId":"OG004","value":".99","spread":".05"}]}]}]},{"type":"SECONDARY","title":"Fasting Blood Glucose","description":"Treatment impact on fasting concentration of glucose in the blood","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":"1.9"},{"groupId":"OG001","value":"93","spread":"2.1"},{"groupId":"OG002","value":"86.5","spread":"1.9"},{"groupId":"OG003","value":"89","spread":"2.0"},{"groupId":"OG004","value":"91.4","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"OGTT Mean Blood Glucose (MBG)","description":"Treatment effect on MBG measured during the oral glucose tolerance test","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":"4.8"},{"groupId":"OG001","value":"126.4","spread":"5.2"},{"groupId":"OG002","value":"112","spread":"4.8"},{"groupId":"OG003","value":"119","spread":"4.9"},{"groupId":"OG004","value":"113","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Fasting Insulin Sensitivity (HOMA-IR)","description":"Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)\\*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.55"},{"groupId":"OG001","value":"3.6","spread":"0.6"},{"groupId":"OG002","value":"2.6","spread":"0.55"},{"groupId":"OG003","value":"3.3","spread":"0.57"},{"groupId":"OG004","value":"3.4","spread":"0.62"}]}]}]},{"type":"SECONDARY","title":"Matsuda Sensitivity Index Derived From the OGTT(SI OGTT)","description":"The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ \\[(G fasting x I fasting) x (G OGTTmean x I OGTTmean)\\], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.6"},{"groupId":"OG001","value":"3.6","spread":"0.7"},{"groupId":"OG002","value":"3.9","spread":"0.6"},{"groupId":"OG003","value":"4.8","spread":"0.6"},{"groupId":"OG004","value":"4.7","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Corrected First Phase Insulin Secretion (IGI/HOMA-IR)","description":"Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"0.2"},{"groupId":"OG001","value":"0.6","spread":"0.21"},{"groupId":"OG002","value":"0.91","spread":"0.2"},{"groupId":"OG003","value":"0.7","spread":"0.2"},{"groupId":"OG004","value":"1.1","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol Levels","description":"Treatment effect on blood concentrations of total cholesterol","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":"10"},{"groupId":"OG001","value":"186","spread":"11"},{"groupId":"OG002","value":"185","spread":"10"},{"groupId":"OG003","value":"192","spread":"11"},{"groupId":"OG004","value":"178","spread":"12"}]}]}]},{"type":"SECONDARY","title":"Triglyceride (TRG) Levels","description":"Treatment effect on blood concentrations of triglycerides","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":"12"},{"groupId":"OG001","value":"132","spread":"13"},{"groupId":"OG002","value":"112","spread":"12"},{"groupId":"OG003","value":"105","spread":"12"},{"groupId":"OG004","value":"110","spread":"13"}]}]}]},{"type":"SECONDARY","title":"Total Testosterone Concentrations","description":"Treatment effect on blood concentrations of total testosterone","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":"4"},{"groupId":"OG001","value":"35","spread":"4.4"},{"groupId":"OG002","value":"42.6","spread":"4"},{"groupId":"OG003","value":"39.5","spread":"4.1"},{"groupId":"OG004","value":"45.5","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Dehydroepiandrosterone Sulfate (DHEA-S) Levels","description":"Treatment effect on blood concentrations of DHEA-S","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":"22"},{"groupId":"OG001","value":"187","spread":"24"},{"groupId":"OG002","value":"169","spread":"22"},{"groupId":"OG003","value":"189","spread":"23"},{"groupId":"OG004","value":"201","spread":"24"}]}]}]},{"type":"SECONDARY","title":"Free Androgen Index (FAI)","description":"Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"0.72"},{"groupId":"OG001","value":"4.7","spread":"0.8"},{"groupId":"OG002","value":"5.2","spread":"0.73"},{"groupId":"OG003","value":"5.7","spread":"0.74"},{"groupId":"OG004","value":"5","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure (SBP)","description":"Treatment effect on SBP after 24 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123.6","spread":"1.9"},{"groupId":"OG001","value":"123","spread":"2.0"},{"groupId":"OG002","value":"122","spread":"1.9"},{"groupId":"OG003","value":"128","spread":"1.8"},{"groupId":"OG004","value":"124","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Diastolic Blood Pressure (DBP)","description":"Treatment effect on DBP after 24 weeks","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":"1.7"},{"groupId":"OG001","value":"79.8","spread":"1.9"},{"groupId":"OG002","value":"76","spread":"1.7"},{"groupId":"OG003","value":"82","spread":"1.8"},{"groupId":"OG004","value":"83.6","spread":"2.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":23},"commonTop":["Yeast infection or urinary tract infection","Nausea and upset stomach","Injection site reaction","Insomnia","Vaginal irritation"]}}}